Organ-based Characterization of B Cells in Patients with Systemic Lupus Erythematosus

Overview

Journal Front Immunol

Date 2025 Feb 7

PMID 39917309

Authors

Yunan Wang

Rui Zhao

Qian Liang

Shiwen Ni

Mei Yang

Liwei Qiu

Juan Ji

Zhifeng Gu

Chen Dong

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) is a chronic, inflammatory, and progressive autoimmune disease. The unclear pathogenesis, high heterogeneity, and prolonged course of the disease present significant challenges for effective clinical management of lupus patients. Dysregulation of the immune system and disruption of immune tolerance, particularly through the abnormal activation of B lymphocytes and the production of excessive autoantibodies, lead to widespread inflammation and tissue damage, resulting in multi-organ impairment. Currently, there is no systematic review that examines the specificity of B cell characteristics and pathogenic mechanisms across various organs. This paper reviews current research on B cells in lupus patients and summarizes the distinct characteristics of B cells in different organs. By integrating clinical manifestations of organ damage in patients with a focus on the organ-specific features of B cells, we provide a new perspective on enhancing the efficacy of lupus-targeted B cell therapy strategies.

References

Dooley M, Houssiau F, Aranow C, DCruz D, Askanase A, Roth D . Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2012; 22(1):63-72. DOI: 10.1177/0961203312465781. View

Zhang W, Wang Y, Hu F, Lu F, Wu T, Feng Y . Dysfunction of CD27IgD B cells correlates with aggravated systemic lupus erythematosus. Clin Rheumatol. 2022; 41(5):1551-1559. DOI: 10.1007/s10067-022-06051-z. View

Wen J, Stock A, Chalmers S, Putterman C . The role of B cells and autoantibodies in neuropsychiatric lupus. Autoimmun Rev. 2016; 15(9):890-5. PMC: 4982790. DOI: 10.1016/j.autrev.2016.07.009. View

Zeng L, Yang K, Wu Y, Yu G, Yan Y, Hao M . Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun. 2024; 148:103291. DOI: 10.1016/j.jaut.2024.103291. View

Jenks S, Cashman K, Woodruff M, Lee F, Sanz I . Extrafollicular responses in humans and SLE. Immunol Rev. 2019; 288(1):136-148. PMC: 6422038. DOI: 10.1111/imr.12741. View

Isenberg D, Spellerberg M, Williams W, Griffiths M, Stevenson F . Identification of the 9G4 idiotope in systemic lupus erythematosus. Br J Rheumatol. 1993; 32(10):876-82. DOI: 10.1093/rheumatology/32.10.876. View

Shen B, Tan W, Feng G, He Y, Liu J, Chen W . The correlations of disease activity, socioeconomic status, quality of life, and depression/anxiety in Chinese patients with systemic lupus erythematosus. Clin Dev Immunol. 2013; 2013:270878. PMC: 3705842. DOI: 10.1155/2013/270878. View

Yang C, Hou X, Feng Q, Li Y, Wang X, Qin L . Lupus serum IgG induces microglia activation through Fc fragment dependent way and modulated by B-cell activating factor. J Transl Med. 2019; 17(1):426. PMC: 6925475. DOI: 10.1186/s12967-019-02175-0. View

Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A . Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(7):2328-37. PMC: 3350827. DOI: 10.1002/art.34400. View

10.

Dong C, Yang N, Zhao R, Yang Y, Gu X, Fu T . SVM-Based Model Combining Patients' Reported Outcomes and Lymphocyte Phenotypes of Depression in Systemic Lupus Erythematosus. Biomolecules. 2023; 13(5). PMC: 10216744. DOI: 10.3390/biom13050723. View

11.

Pottier V, Pierrot M, Subra J, Mercat A, Kouatchet A, Parrot A . Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus. 2011; 20(6):656-9. DOI: 10.1177/0961203310386276. View

12.

Chernova I, Song W, Steach H, Hafez O, Al Souz J, Chen P . The ion transporter Na-K-ATPase enables pathological B cell survival in the kidney microenvironment of lupus nephritis. Sci Adv. 2023; 9(5):eadf8156. PMC: 9891690. DOI: 10.1126/sciadv.adf8156. View

13.

Nakano M, Iwasaki Y, Fujio K . Transcriptomic studies of systemic lupus erythematosus. Inflamm Regen. 2021; 41(1):11. PMC: 8033719. DOI: 10.1186/s41232-021-00161-y. View

14.

Mockel T, Basta F, Weinmann-Menke J, Schwarting A . B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2020; 20(2):102736. DOI: 10.1016/j.autrev.2020.102736. View

15.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

16.

Pan L, Lu M, Wang J, Xu M, Yang S . Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2019; 16(1):19-30. PMC: 7040062. DOI: 10.1007/s12519-019-00229-3. View

17.

Su Y, Li F, Sheu J, Li S, Weng S, Shen F . A Study on MDA5 Signaling in Splenic B Cells from an Imiquimod-Induced Lupus Mouse Model with Proteomics. Cells. 2022; 11(21). PMC: 9657434. DOI: 10.3390/cells11213350. View

18.

Jackson S, Scharping N, Kolhatkar N, Khim S, Schwartz M, Li Q . Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol. 2014; 192(10):4525-32. PMC: 4041708. DOI: 10.4049/jimmunol.1400098. View

19.

Devarapu S, Anders H . Toll-like receptors in lupus nephritis. J Biomed Sci. 2018; 25(1):35. PMC: 5898010. DOI: 10.1186/s12929-018-0436-2. View

20.

Richardson C, Chida A, Adlowitz D, Silver L, Fox E, Jenks S . Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol. 2013; 191(10):4926-39. PMC: 3816606. DOI: 10.4049/jimmunol.1202263. View